These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 1313173)

  • 61. Intermittent, alternating, and concurrent regimens of zidovudine and 2'-3' dideoxycytidine in the LP-BM5 murine induced immunodeficiency model.
    Basham T; Holdener T; Merigan T
    J Infect Dis; 1991 Apr; 163(4):869-72. PubMed ID: 1849164
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Researchers are rethinking role of AZT in drug therapy.
    AIDS Policy Law; 1995 Oct; 10(18):11. PubMed ID: 11362821
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Potential chemoprotectant activity of 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC) against ricin toxicity in Chinese hamster ovary and macrophage J774A.1 cell cultures.
    Hassoun EA; Stohs SJ
    J Appl Toxicol; 1996; 16(1):43-8. PubMed ID: 8821674
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics of 2',3'-dideoxycytidine after high-dose administration to rats.
    Ibrahim SS; Boudinot FD
    J Pharm Sci; 1991 Jan; 80(1):36-8. PubMed ID: 1849573
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacokinetics of zidovudine in patients with liver cirrhosis.
    Taburet AM; Naveau S; Zorza G; Colin JN; Delfraissy JF; Chaput JC; Singlas E
    Clin Pharmacol Ther; 1990 Jun; 47(6):731-9. PubMed ID: 2357867
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides.
    Pizzo PA
    Am J Med; 1990 May; 88(5B):16S-19S. PubMed ID: 2159704
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 3"-Azido-3'-deoxythymidine and 2',3'-dideoxycytidine do not inhibit gene-specific DNA repair in hamster cells.
    Link CJ; Bohr VA
    Biochem Biophys Res Commun; 1995 Mar; 208(1):198-203. PubMed ID: 7887930
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 2', 3'-Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cells.
    Han T; Fernandez M; Sarkar M; Agarwal RP
    Life Sci; 2004 Jan; 74(7):835-42. PubMed ID: 14659972
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.
    Eron JJ; Johnson VA; Merrill DP; Chou TC; Hirsch MS
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1559-62. PubMed ID: 1324648
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.
    LaCasse RA; Remington KM; North TW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):26-32. PubMed ID: 8624757
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease.
    Kimmel PL; Lew SQ; Umana WO; Li PP; Gordon AM; Straw J
    Blood Purif; 1995; 13(6):340-6. PubMed ID: 8821198
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.
    Richman DD
    Am J Med; 1990 May; 88(5B):8S-10S. PubMed ID: 2186629
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.
    Ruhnke M; Bauer FE; Seifert M; Trautmann M; Hille H; Koeppe P
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2153-8. PubMed ID: 8257138
    [TBL] [Abstract][Full Text] [Related]  

  • 75. New depot forms of AZT and 3TC based on their phosphonate derivatives: anti-HIV activity and pharmacokinetic parameters.
    Kukhanova MK; Jasco MV; Shipitzyn AV; Yanvarev DV; Khandazhynskaya AL
    Nucleic Acids Symp Ser (Oxf); 2008; (52):597-8. PubMed ID: 18776521
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
    Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
    J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers.
    Hedaya MA; Elmquist WF; Sawchuk RJ
    Pharm Res; 1990 Apr; 7(4):411-7. PubMed ID: 2362917
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
    Johnson VA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeted therapy of human immunodeficiency virus-related disease.
    Mitsuya H; Yarchoan R; Kageyama S; Broder S
    FASEB J; 1991 Jul; 5(10):2369-81. PubMed ID: 1712326
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs.
    Viora M; Di Genova G; Rivabene R; Malorni W; Fattorossi A
    Int J Immunopharmacol; 1997 Jun; 19(6):311-21. PubMed ID: 9467750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.